Bexsero

Bexsero. It is a recombinant protein vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. The vaccine was developed by the pharmaceutical company Novartis and is now marketed by GlaxoSmithKline following an asset exchange. Its approval marked a significant advancement in combating a major cause of meningitis and septicemia, particularly in infants and adolescents.

Medical uses

Bexsero is approved for use in individuals from two months of age and older. It is primarily administered to protect against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, a leading bacterial cause of meningitis and sepsis worldwide. The immunization schedule varies by age, with the European Medicines Agency and the U.S. Food and Drug Administration providing specific guidelines for infants, children, and adults. The vaccine is often incorporated into national immunization programs, such as those in the United Kingdom and Australia, and is recommended for individuals at increased risk, including those with complement deficiency or functional asplenia, and during outbreaks at institutions like Princeton University and University of California, Santa Barbara.

Adverse effects

Common adverse reactions to Bexsero include pain and swelling at the injection site, fever, irritability in infants, and headache in older recipients. More serious but rare events can include febrile seizures, particularly in young children, and potential hypersensitivity reactions. Post-marketing surveillance, coordinated by bodies like the Centers for Disease Control and Prevention and the World Health Organization, continues to monitor the vaccine's safety profile. The overall benefit-risk assessment strongly favors immunization, given the severity of invasive meningococcal disease, a stance supported by data from the Vaccine Adverse Event Reporting System and studies published in journals like The Lancet and the New England Journal of Medicine.

Mechanism of action

Bexsero employs a multi-component approach, containing three recombinant proteins—Neisserial Heparin Binding Antigen (NHBA), Neisseria adhesin A (NadA), and factor H binding protein (fHbp)—identified via reverse vaccinology. These antigens are derived from the Neisseria meningitidis bacterium and are formulated with an outer membrane vesicle (OMV) from the New Zealand outbreak strain NZ98/254. The combination elicits a broad immune response, producing opsonophagocytic antibodies that facilitate the destruction of the meningococcal bacteria by the host's immune system, a process critical for preventing bacteremia and subsequent meningitis.

History

The development of Bexsero was pioneered by the research team at Novartis Vaccines, utilizing genomic sequencing and reverse vaccinology techniques pioneered at the J. Craig Venter Institute. Following extensive clinical trials across multiple continents, it received its first marketing authorization from the European Commission in January 2013. Approval by the U.S. Food and Drug Administration followed in January 2015. The acquisition of Novartis's vaccines business by GlaxoSmithKline in 2015 transferred ownership of the product. Key clinical evidence was gathered during outbreaks at Princeton University and the University of California, Santa Barbara, which demonstrated its real-world effectiveness.

Society and culture

The introduction of Bexsero has had a substantial impact on public health policy and parental choice regarding immunization. Its incorporation into the national infant immunization schedule in the United Kingdom in 2015, following a recommendation from the Joint Committee on Vaccination and Immunisation, represented a major public health initiative. The vaccine's role in controlling campus outbreaks in the United States was widely covered by media outlets like the BBC and The New York Times. The high cost of the vaccine has sparked discussions on healthcare economics and access within systems like the National Health Service and private insurers in the United States.

Category:Vaccines Category:Antibacterial drugs